Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Disease control, visual and anatomic outcomes at week 48 of brolucizumab treatment in patients with previously suboptimal anatomically controlled neovascular age-related macular degeneration - The SWIFT study.

Journal francais d'ophtalmologie·2025

Same author

[Recommendations for rational use of new anti-VEGF biologicals].

Journal francais d'ophtalmologie·2025

Same author

Cognitive bias evaluation on the choice of treatment in common retinal disorders among retina specialists in 2023.

Journal francais d'ophtalmologie·2024

Same author

Bilateral yellowish prefoveal dots in autoimmune hemolytic anemia secondary to myelodysplastic syndrome: Case report.

Journal francais d'ophtalmologie·2019

Same author

[Update from France Macula Federation: Treatment of Wet AMD].

Journal francais d'ophtalmologie·2018

Same author

[Update from France Macula Federation: Diagnosis of wet AMD].

Journal francais d'ophtalmologie·2018

Same journal

Real-time documentation of acute pre-retinal hemorrhage in central retinal vein occlusion.

Journal francais d'ophtalmologie·2026

Same journal

Incidental detection of benign lobular inner nuclear layer proliferations (BLIPs) in a young adult.

Journal francais d'ophtalmologie·2026

Same journal

Combined autonomic and cranial neuropathy following radiofrequency ablation for trigeminal neuralgia.

Journal francais d'ophtalmologie·2026

Same journal

[Point-of-care biomarkers of ocular surface disease: Current approaches and future perspectives].

Journal francais d'ophtalmologie·2026

Same journal

Granulomatous reaction after hybrid hyaluronic acid-calcium hydroxyapatite filler injection in supratarsal hollow correction.

Journal francais d'ophtalmologie·2026

Same journal

Sequential dexamethasone and fluocinolone acetonide intravitreal implants to treat macular edema in non-infectious uveitis.

Journal francais d'ophtalmologie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

[AMD: Future therapies].

S Y Cohen¹, J-F Girmens

¹Centre ophtalmologique d'imagerie et de laser, 11, rue Antoine-Bourdelle, 75015 Paris, France. sycsyc75@gmail.com

Journal Francais D'Ophtalmologie

|June 11, 2011

Summary

This summary is machine-generated.

New drugs are being developed for both forms of age-related macular degeneration (AMD). Treatments focus on protecting retinal cells in atrophic AMD and targeting new pathways beyond anti-VEGF in exudative AMD.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Related Experiment Videos

Last Updated: Jun 1, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium

Published on: August 7, 2015

Area of Science:

Ophthalmology
Retinal Diseases
Drug Development

Context:

Age-related macular degeneration (AMD) is a leading cause of vision loss.
Current treatments for exudative AMD primarily involve anti-VEGF therapies.
Atrophic and exudative AMD represent distinct pathological forms requiring different therapeutic strategies.

Purpose:

To review current and emerging drug therapies for both geographic atrophy (atrophic AMD) and exudative AMD.
To summarize data presented at scientific meetings and from pharmaceutical companies.
To provide an overview of novel therapeutic targets beyond anti-VEGF for exudative AMD.

Summary:

Investigational drugs for atrophic AMD aim to prevent photoreceptor and retinal pigment epithelium damage by targeting oxidative stress and inflammation.
Emerging treatments for exudative AMD are exploring alternatives or adjuncts to anti-VEGF therapies.
New approaches target mechanisms like angiogenesis and cells such as pericytes to improve visual outcomes.

Impact:

This review offers insights into the evolving landscape of AMD therapeutics.
It highlights potential advancements for patients with both major forms of AMD.
Understanding these developments is crucial for clinicians and researchers in the field.